Evoke Pharma Inc (EVOK) News & EventsEVOKNews & EventsEvoke Pharma Inc

Evoke Pharma announces Q3 earnings per share of 45 cents, compared to a loss of 94 cents in the same period last year.

Reports Q3 revenue $4.28M vs $2.65M last year. "The proposed transaction with QOL Medical reflects this progress and the strategic value we've built around GIMOTI and across the broader GI community," commented Matt D'Onofrio, Chief Executive Officer of Evoke Pharma. "We are proud of the consistent execution that led to another quarter of strong sales growth, with net product sales up over 60% year-over-year," D'Onofrio added.

QOL Medical to purchase Evoke Pharma for $11.00 per share in cash

Evoke Pharma and QOL Medical entered into a definitive agreement pursuant to which QOL Medical will acquire Evoke for $11.00 per share in cash at closing. The transaction has been unanimously approved by the Boards of Directors of both companies and will be conducted via a tender offer. The transaction, expected to close by the end of 2025, reflects the strategic value of its commercial product, GIMOTI, the first and only FDA-approved nasal spray formulation of metoclopramide for the treatment of acute and recurrent diabetic gastroparesis in adults. The purchase price represents a premium of 139.7% to Evoke's closing share price on November 3, 2025. Under the terms of the merger agreement, QOL Medical, through a subsidiary, will initiate a tender offer to acquire all outstanding shares of Evoke at a price of $11.00 per share in cash at closing. The closing of the tender offer will be subject to certain conditions, including the tender of at least a majority of the outstanding shares of Evoke at such time, and other customary closing conditions. Upon the successful completion of the tender offer, a subsidiary of QOL Medical will merge into Evoke and any remaining shares of common stock of Evoke will be cancelled and converted into the right to receive the same price per share payable in the tender offer. The transaction is not subject to a financing condition and QOL Medical intends to finance the transaction using cash on hand. The transaction is expected to close in the fourth quarter of 2025, subject to the terms of the merger agreement.

Evoke Pharma and EVERSANA Enhance GIMOTI Availability Through Partnership with Omnicell

Evoke Pharma (EVOK) together with EVERSANA announced the addition of Omnicell (OMCL). This relationship is expected to expand patient access to GIMOTI, the only FDA-approved nasal spray for adults with acute and recurrent diabetic gastroparesis specifically, into large gastroenterology organizations. As part of Evoke's strategy to broaden GIMOTI's reach through key pharmacy partnerships, the addition of Omnicell is meant to ensure better alignment with specialty pharmacies used by large gastroenterology group practices, like Gastro Health, which has a presence in 7 states and 150 locations. This relationship is expected to almost double the number of specialty pharmacies available to access Gimoti.